
Personalis PSNL
$ 15.76
1.48%
Personalis Total Current Liabilities | PSNL
Annual Total Current Liabilities Personalis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.6 M | 31.1 M | 47.2 M | 33.1 M | 31.3 M | 40.6 M | 50 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50 M | 31.1 M | 39 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | ||
|
Syneos Health
SYNH
|
1.72 B | - | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Renalytix AI plc
RNLX
|
11.5 M | - | 5.66 % | $ 22.7 M | ||
|
Psychemedics Corporation
PMD
|
2.71 M | - | -1.84 % | $ 15.3 M | ||
|
Meridian Bioscience
VIVO
|
58 M | - | - | $ 1.49 B | ||
|
Celcuity
CELC
|
44.2 M | $ 66.73 | 3.9 % | $ 3.12 B | ||
|
DexCom
DXCM
|
2.14 B | $ 79.42 | -5.97 % | $ 31 B | ||
|
Agilent Technologies
A
|
2.35 B | $ 175.14 | 1.97 % | $ 49.7 B | ||
|
Castle Biosciences
CSTL
|
68.7 M | $ 32.49 | -4.99 % | $ 942 M | ||
|
Anixa Biosciences
ANIX
|
1.97 M | $ 3.16 | 4.29 % | $ 103 K | ||
|
Biodesix
BDSX
|
17.4 M | $ 8.51 | -57.13 % | $ 64.3 M | ||
|
BioNano Genomics
BNGO
|
22.9 M | $ 1.15 | 4.54 % | $ 6.26 M | ||
|
Bioventus
BVS
|
160 M | $ 10.61 | -0.66 % | $ 707 M | ||
|
Fulgent Genetics
FLGT
|
85 M | $ 23.68 | 26.9 % | $ 729 M | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 78.47 | 2.8 % | $ 4.18 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
2.48 M | $ 1.61 | -1.55 % | $ 4.69 M | ||
|
Interpace Biosciences
IDXG
|
5.1 M | $ 7.0 | -13.43 % | $ 31 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
3.2 B | $ 204.67 | 1.5 % | $ 16.1 B | ||
|
Co-Diagnostics
CODX
|
3.54 M | $ 0.25 | -8.24 % | $ 333 K | ||
|
Burning Rock Biotech Limited
BNR
|
247 M | $ 13.2 | -0.38 % | $ 139 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
DarioHealth Corp.
DRIO
|
9.32 M | $ 2.4 | -11.93 % | $ 9.56 M | ||
|
Myriad Genetics
MYGN
|
134 M | $ 5.97 | -5.17 % | $ 553 M | ||
|
ENDRA Life Sciences
NDRA
|
751 K | $ 4.73 | -5.49 % | $ 3.72 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 16.85 | 2.18 % | $ 2.16 B | ||
|
OPKO Health
OPK
|
147 M | $ 1.72 | -1.71 % | $ 1.29 B | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 2.3 | -5.35 % | $ 690 M | ||
|
Neogen Corporation
NEOG
|
158 M | $ 11.75 | 0.6 % | $ 2.56 B | ||
|
Precipio
PRPO
|
3.75 M | $ 18.95 | 2.02 % | $ 30.4 M | ||
|
Sotera Health Company
SHC
|
250 M | $ 16.01 | 0.88 % | $ 4.55 B | ||
|
Quidel Corporation
QDEL
|
337 M | $ 10.69 | -16.78 % | $ 450 M | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | ||
|
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M | ||
|
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
36.6 M | $ 25.62 | 0.55 % | $ 573 M | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 120.83 | 0.18 % | $ 7.23 B | ||
|
Organovo Holdings
ONVO
|
2.78 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
4.55 M | - | -16.95 % | $ 1.54 M | ||
|
PerkinElmer
PKI
|
1.33 B | - | -0.91 % | $ 14.7 B | ||
|
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B |